AGTR1 and Parkinson disease: AT1R inhibition has shown functional benefits in preclinical models of stroke (Wanderer et al., 2020), Alzheimer’s (Mogi and Horiuchi, 2009), and Parkinson’s disease (Labandeira et al., 2022).